STUDY CONFIRMS COVID VACCINES INCREASE RISK OF HEAVY MENSTRUAL BLEEDING – National study from France found 20% increased risk of heavy bleeding
A new national study from France found that COVID-19 vaccines are linked to a more than 20% increased risk of heavy menstrual bleeding in the first three months following the primary vaccination series.
Researchers from EPI-PHARE, part of the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, conducted a “case-control study” using comprehensive data from the French National Health Data System.
They were investigating how to better measure the risk of heavy menstrual bleeding following COVID-19 vaccination reported across the world soon after the vaccines were rolled out.
The study included women ages 15-50 who were not pregnant and were hospitalised with heavy menstrual bleeding between May 12, 2021 — when the COVID-19 vaccine was made available to all French adults — and Aug. 31, 2022. They certainly found a meaningful correlation. This study endpoint was increased in those having received a last dose of COVID-19 mRNA primary vaccination in the preceding 1–3 months
In the study period, about 71% of the women in the case group and 70% of women in the control group had received at least one dose of the vaccine. Almost all of the women had taken either the Pfizer or the Moderna shot.
